Risedronate In The Prevention Of Osteoporosis In Osteopenic Postmenopausal Women
Status:
Completed
Trial end date:
2005-04-01
Target enrollment:
Participant gender:
Summary
To confirm the superiority of 5 mg daily risedronate as compared to placebo in maintaining or
increasing bone mass in lumbar spine in osteopenic postmenopausal women
To confirm the efficacy of 5 mg daily risedronate in osteopenic postmenopausal women in
maintaining or increasing bone mass in proximal femur and decreasing bone resorption
To confirm general safety of 5 mg daily risedronate as compared to placebo